Unnamed: 0,title,date,stock,sentiment
216120.0,CymaBay Therapeutics shares are trading higher after HC Wainwright upgraded the stock from Neutral to Buy and announced a price target of $9 per share.,2020-05-26 09:11:00-04:00,CBAY,positive
216121.0,"HC Wainwright & Co. Upgrades CymaBay Therapeutics to Buy, Announces $9 Price Target",2020-05-26 07:29:00-04:00,CBAY,neutral
216122.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,CBAY,negative
216123.0,"Benzinga's Top Upgrades, Downgrades For May 13, 2020",2020-05-13 09:58:00-04:00,CBAY,positive
216124.0,10 Biggest Price Target Changes For Wednesday,2020-05-13 09:15:00-04:00,CBAY,neutral
216125.0,"B. Riley FBR Upgrades CymaBay Therapeutics to Buy, Raises Price Target of $6",2020-05-13 06:52:00-04:00,CBAY,neutral
216126.0,84 Biggest Movers From Yesterday,2020-05-13 05:31:00-04:00,CBAY,neutral
216127.0,"Diverging NASH Stories: CymaBay On Track To Restart, GenFit's Drug Flunks Late-Stage Study",2020-05-12 16:01:00-04:00,CBAY,negative
216128.0,Mid-Afternoon Market Update: Dow Falls 150 Points; Eventbrite Shares Tumble On Downbeat Q1 Results,2020-05-12 14:35:00-04:00,CBAY,positive
216129.0,Mid-Day Market Update: Crude Oil Rises Over 7%; Genfit Shares Plummet,2020-05-12 12:39:00-04:00,CBAY,negative
216130.0,60 Stocks Moving In Tuesday's Mid-Day Session,2020-05-12 12:26:00-04:00,CBAY,neutral
216131.0,"UPDATE: SVB Leerink Upgrades CymaBay Therapeutics To Outperform, Raises Target To $6 Notes Seladelpar 'findings are a near-best case scenario for CBAY, in our view, and would appear to reopen the door to develop seladelpar in both PBC and NASH'",2020-05-12 12:23:00-04:00,CBAY,neutral
216132.0,"UPDATE: Raymond James Upgrades CymaBay Therapeutics To Outperform, Announces $7 Target Notes 'Pending FDA agreement to lift the current clinical hold, seladelpar is back. The development is stunning'",2020-05-12 12:14:00-04:00,CBAY,positive
216133.0,A Look Into CymaBay Therapeutics Price Over Earnings,2020-05-12 10:34:00-04:00,CBAY,neutral
216134.0,"Benzinga's Top Upgrades, Downgrades For May 12, 2020",2020-05-12 09:51:00-04:00,CBAY,positive
216135.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,CBAY,negative
216136.0,10 Biggest Price Target Changes For Tuesday,2020-05-12 08:03:00-04:00,CBAY,neutral
216137.0,20 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-05-12 07:33:00-04:00,CBAY,neutral
216138.0,"Cantor Fitzgerald Reiterates Overweight on CymaBay Therapeutics, Raises Price Target to $15",2020-05-12 07:28:00-04:00,CBAY,negative
216139.0,"Stifel Upgrades CymaBay Therapeutics to Buy, Raises Price Target of $8",2020-05-12 07:24:00-04:00,CBAY,neutral
216140.0,32 Stocks Moving in Tuesday's Pre-Market Session,2020-05-12 07:16:00-04:00,CBAY,neutral
216141.0,CymaBay shares are trading higher after the company announced an independent expert panel unanimously concluded there is no evidence of liver injury in the Phase 2b NASH study of seladelpar. The panel supported re-initiating development of seladelpar.,2020-05-12 06:53:00-04:00,CBAY,negative
216142.0,"SVB Leerink Upgrades CymaBay Therapeutics to Outperform, Raises Price Target to $6",2020-05-12 06:48:00-04:00,CBAY,neutral
216143.0,"Evercore ISI Group Upgrades CymaBay Therapeutics to Outperform, Announces $15 Price Target",2020-05-12 06:22:00-04:00,CBAY,neutral
216144.0,"Raymond James Upgrades CymaBay Therapeutics to Outperform, Announces $7 Price Target",2020-05-12 06:21:00-04:00,CBAY,neutral
216145.0,14 Stocks Moving In Monday's After-Hours Session,2020-05-11 17:19:00-04:00,CBAY,neutral
216146.0,CymaBay Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.,2020-05-11 16:14:00-04:00,CBAY,positive
216147.0,CymaBay Therapeutics Q1 EPS $(0.190) Beats $(0.300) Estimate,2020-05-11 16:04:00-04:00,CBAY,neutral
216148.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,CBAY,neutral
216149.0,"Citigroup Maintains Buy on CymaBay Therapeutics, Lowers Price Target to $1.6",2020-03-20 09:12:00-04:00,CBAY,negative
216150.0,"B. Riley FBR Maintains Neutral on CymaBay Therapeutics, Lowers Price Target to $1.5",2020-03-18 07:00:00-04:00,CBAY,negative
216151.0,"Benzinga's Top Upgrades, Downgrades For March 13, 2020",2020-03-13 10:20:00-04:00,CBAY,positive
216152.0,"Cantor Fitzgerald Upgrades CymaBay Therapeutics to Overweight, Raises Price Target to $5",2020-03-13 07:10:00-04:00,CBAY,negative
216153.0,CymaBay Therapeutics Q4 EPS $(0.43) Misses $(0.39) Estimate,2020-03-12 16:01:00-04:00,CBAY,negative
216154.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,CBAY,negative
216155.0,"Citi Downgrades Intercept, Says NASH Launch Is Appropriately Priced In",2020-01-02 12:40:00-05:00,CBAY,neutral
216156.0,28 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-12-20 08:19:00-05:00,CBAY,neutral
216157.0,21 Stocks Moving in Friday's Pre-Market Session,2019-12-20 07:34:00-05:00,CBAY,neutral
216158.0,"CymaBay Therapeutics To Reduce Workforce By 60%, Explore Strategic Opportunities With Regard To Its Development",2019-12-19 17:36:00-05:00,CBAY,positive
216159.0,Newtyn Management Reports 5.4% Passive Stake In CymaBay Therapeutics,2019-12-13 14:41:00-05:00,CBAY,positive
216160.0,CymaBay Therapeutics shares are trading higher. Not seeing any news to justify the price action. NOTE: The stock is trading on above-average volume.,2019-12-13 11:55:00-05:00,CBAY,positive
216161.0,UPDATE: Raymond James Downgrades CymaBay Therapeutics To Market Perform 'given the unexpected setback for seladelpar (all programs terminated or halted on Monday 11/25) and uncertainty around any path forward for the lead PBC program',2019-11-26 13:47:00-05:00,CBAY,negative
216162.0,"Roth Capital Downgrades CymaBay Therapeutics to Neutral, Lowers Price Target to $2",2019-11-26 10:09:00-05:00,CBAY,negative
216163.0,"Benzinga's Top Upgrades, Downgrades For November 26, 2019",2019-11-26 09:59:00-05:00,CBAY,positive
216164.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,CBAY,positive
216165.0,Cantor Fitzgerald Downgrades CymaBay Therapeutics to Neutral,2019-11-26 07:48:00-05:00,CBAY,neutral
216166.0,45 Biggest Movers From Yesterday,2019-11-26 07:05:00-05:00,CBAY,neutral
216167.0,Raymond James Downgrades CymaBay Therapeutics to Market Perform,2019-11-26 06:24:00-05:00,CBAY,neutral
216168.0,Mid-Afternoon Market Update: Dow Rises 150 Points; Sorrento Therapeutics Shares Spike Higher,2019-11-25 15:20:00-05:00,CBAY,positive
216169.0,Oppenheimer Downgrades CymaBay Therapeutics to Perform,2019-11-25 12:53:00-05:00,CBAY,neutral
216170.0,"CymaBay Halts Study On Lead Clinical Program, Stock Crashes",2019-11-25 12:36:00-05:00,CBAY,neutral
216171.0,33 Stocks Moving In Monday's Mid-Day Session,2019-11-25 12:28:00-05:00,CBAY,neutral
216172.0,Mid-Day Market Update: Medicines Company Jumps Following Acquisition News; CymaBay Therapeutics Shares Plunge,2019-11-25 12:10:00-05:00,CBAY,positive
216173.0,Stocks That Hit 52-Week Lows On Monday,2019-11-25 11:15:00-05:00,CBAY,negative
216174.0,Evercore ISI Group Downgrades CymaBay Therapeutics to In-Line,2019-11-25 10:31:00-05:00,CBAY,neutral
216175.0,"Mid-Morning Market Update: Markets Open Higher; Schwab, TD Ameritrade Confirm $26B Merger",2019-11-25 10:15:00-05:00,CBAY,neutral
216176.0,Stifel Downgrades CymaBay Therapeutics to Hold,2019-11-25 09:23:00-05:00,CBAY,neutral
216177.0,36 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-25 08:40:00-05:00,CBAY,neutral
216178.0,CymaBay Therapeutics shares are trading lower after the company reported a halt in the clinical development of its Seladelpar.,2019-11-25 08:40:00-05:00,CBAY,neutral
216179.0,CymaBay Therapeutics Reports Halt In Clinical Development Of Seladelpar,2019-11-25 08:12:00-05:00,CBAY,neutral
216180.0,60 Biggest Movers From Yesterday,2019-11-07 05:44:00-05:00,CBAY,neutral
216181.0,62 Stocks Moving In Wednesday's Mid-Day Session,2019-11-06 13:48:00-05:00,CBAY,neutral
216182.0,CymaBay Therapeutics Q3 EPS $(0.38) Misses $(0.37) Estimate,2019-11-05 16:36:00-05:00,CBAY,negative
216183.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,CBAY,negative
216184.0,CymaBay Therapeutics Reaches Target Enrollment In ENHANCE Global Phase 3 Study Evaluating Seladelpar For Primary Biliary Cholangitis,2019-11-04 08:14:00-05:00,CBAY,positive
216185.0,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",2019-10-11 08:14:00-04:00,CBAY,positive
216186.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-10 11:08:00-04:00,CBAY,negative
216187.0,"The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",2019-10-10 07:31:00-04:00,CBAY,neutral
216188.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-09 12:55:00-04:00,CBAY,negative
216189.0,"The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug",2019-10-09 07:58:00-04:00,CBAY,negative
216190.0,"The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts",2019-09-18 07:39:00-04:00,CBAY,neutral
216191.0,CymaBay Therapeutics Option Alert: Jan 17 $7.5 Calls Sweep (2) near the Ask: 2648 @ $0.676 vs 875 OI; Ref=$5.55,2019-08-08 11:12:00-04:00,CBAY,positive
216192.0,CymaBay Therapeutics Q2 EPS $(0.35) Beats $(0.37) Estimate,2019-08-07 16:13:00-04:00,CBAY,neutral
216193.0,"The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership",2019-06-25 07:15:00-04:00,CBAY,neutral
216194.0,"Stifel Nicolaus Initiates Coverage On CymaBay Therapeutics with Buy Rating, Announces $14 Price Target",2019-06-25 06:45:00-04:00,CBAY,neutral
216195.0,CymaBay Therapeutics Announces IND To Commence Clinical Study Of Seladelpar To Treat Primary Sclerosing Cholangitis,2019-06-18 08:13:00-04:00,CBAY,positive
216196.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,CBAY,positive
216197.0,A Look At Benzinga Pro's Most-Searched Tickers For June 12,2019-06-12 11:49:00-04:00,CBAY,neutral
216198.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wed., Jun. 12, 2019",2019-06-12 10:02:00-04:00,CBAY,positive
216199.0,"UPDATE: Raymond James Upgrades CymaBay Therapeutics To Strong Buy As Firm Notes '1) NASH is now a ""free call option"", 2) PBC provides ""valuation floor,"" 3) market reaction to surrogate endpoint data is ""overblown""'",2019-06-12 09:43:00-04:00,CBAY,positive
216200.0,"Benzinga's Top Upgrades, Downgrades For June 12, 2019",2019-06-12 09:07:00-04:00,CBAY,positive
216201.0,30 Stocks Moving In Wednesday's Pre-Market Session,2019-06-12 08:20:00-04:00,CBAY,neutral
216202.0,"The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana",2019-06-12 07:34:00-04:00,CBAY,neutral
216203.0,Raymond James Upgrades CymaBay Therapeutics to Strong Buy,2019-06-12 06:46:00-04:00,CBAY,positive
216204.0,66 Biggest Movers From Yesterday,2019-06-12 04:44:00-04:00,CBAY,neutral
216205.0,"CymaBay Therapeutics Shares Slightly Higher After Hours As Hearing Raymond James Upgraded To Strong Buy, Set $19 Price Target",2019-06-11 16:12:00-04:00,CBAY,positive
216206.0,Mid-Afternoon Market Update: U.S. Stocks Turn Lower; Casey's General Stores Shares Surge On Earnings Beat,2019-06-11 14:57:00-04:00,CBAY,neutral
216207.0,48 Stocks Moving In Tuesday's Mid-Day Session,2019-06-11 12:36:00-04:00,CBAY,neutral
216208.0,Mid-Day Market Update: Chico's FAS Rises On Upbeat Earnings; CymaBay Therapeutics Shares Plummet,2019-06-11 12:22:00-04:00,CBAY,positive
216209.0,Mid-Morning Market Update: Markets Open Higher; H & R Block Earnings Top Expectations,2019-06-11 10:12:00-04:00,CBAY,negative
216210.0,CymaBay Therapeutics shares are trading lower after the company reported data from its Phase 2b study of Seladelpar in patients with nonalcoholic steatohepatitis. Data showed reductions in liver fat were minimal and not significant compared to the placebo.,2019-06-11 09:38:00-04:00,CBAY,negative
216211.0,Viking Therapeutics Shares Up 5.7% Following Concerning Data From A Phase 2b Study Of Seladelpar In Patients With Nonaloholic Steatohepatitis By CymaBay Therapeutics,2019-06-11 09:25:00-04:00,CBAY,positive
216212.0,CymaBay Therapeutics Plummets 40% Following Liver Disease Data,2019-06-11 08:30:00-04:00,CBAY,neutral
216213.0,31 Stocks Moving In Tuesday's Pre-Market Session,2019-06-11 08:09:00-04:00,CBAY,neutral
216214.0,"CymaBay Therapeutics Reports Data From Phase 2b Study Of Seladelpar In Patients With Nonalcoholic Steatohepatitis; Reductions In Liver Fat Were Minimal, Not Significant Compared To Placebo, Reductions In Markers Of Liver Injury Were Clinically Meaningful",2019-06-11 07:05:00-04:00,CBAY,negative
216215.0,CymaBay Therapeutics Option Alert: Jul 19 $17.5 Calls at the Ask: 500 @ $0.7 vs 50 OI; Ref=$11.4,2019-06-07 14:58:00-04:00,CBAY,positive
216216.0,44 Stocks Moving In Friday's Mid-Day Session,2019-06-07 12:50:00-04:00,CBAY,neutral
216217.0,CymaBay Highlights Presentation Of Data At Digestive Disease Week On Results From Seladelpar Program For Treatment Of Primary Biliary Diseases,2019-05-20 16:02:00-04:00,CBAY,neutral
216218.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-05-18 09:50:00-04:00,CBAY,neutral
216219.0,"Citigroup Initiates Coverage On CymaBay Therapeutics Inc. - Common Stock with Buy Rating, Announces $21 Price Target",2019-05-14 07:18:00-04:00,CBAY,neutral
216220.0,CymaBay Therapeutics Inc. - Common Stock Q1 EPS $(0.37) Misses $(0.34) Estimate,2019-05-08 16:40:00-04:00,CBAY,negative
216221.0,CymaBay Therapeutics Inc. Q1 EPS $(0.37) Misses $(0.34) Estimate,2019-05-08 16:07:00-04:00,CBAY,negative
216222.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,CBAY,negative
216223.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,CBAY,positive
216224.0,32 Stocks Moving In Tuesday's Pre-Market Session,2019-04-02 08:20:00-04:00,CBAY,neutral
216225.0,30 Stocks Moving In Wednesday's Pre-Market Session,2019-03-06 08:00:00-05:00,CBAY,neutral
216226.0,"The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split",2019-03-06 07:39:00-05:00,CBAY,negative
216227.0,"10 Stocks To Watch For March 6, 2019",2019-03-06 04:37:00-05:00,CBAY,neutral
216228.0,5 Stocks Moving In Tuesday's After-Hours Session,2019-03-05 16:45:00-05:00,CBAY,neutral
216229.0,"CymaBay Reports Offering Of Common Stock, No Size Disclosed",2019-03-05 16:37:00-05:00,CBAY,negative
216230.0,CymaBay Therapeutics Inc. Q4 EPS $(0.32) Beats $(0.36) Estimate,2019-02-28 16:14:00-05:00,CBAY,neutral
216231.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,CBAY,positive
216232.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-02-19 13:01:00-05:00,CBAY,neutral
216233.0,CymaBay Therapeutics shares are trading higher after the company announced early enrollment of its Phase 2b study of Seladelpar in patients with non-alcoholic steatohepatitis.,2019-02-19 09:04:00-05:00,CBAY,positive
216234.0,CymaBay Therapeutics Announces Early Enrollment Of Phase 2b Study Of Seladelpar In Patients With Nonalcoholic Steatohepatitis,2019-02-19 08:07:00-05:00,CBAY,neutral
216235.0,CymaBay shares are trading higher after the company's Seladelpar was granted breakthrough therapy designation by the FDA for the treatment of Primary Biliary Cholangitis.,2019-02-15 08:39:00-05:00,CBAY,positive
216236.0,CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation By FDA For The Treatment Of Primary Biliary Cholangitis,2019-02-15 08:04:00-05:00,CBAY,positive
216237.0,30 Stocks Moving In Thursday's Pre-Market Session,2019-02-14 08:07:00-05:00,CBAY,neutral
216238.0,"Benzinga's Top Upgrades, Downgrades For February 6, 2019",2019-02-06 09:14:00-05:00,CBAY,positive
216239.0,"B. Riley FBR Initiates Coverage On CymaBay Therapeutics with Neutral Rating, Announces $9 Price Target",2019-02-06 08:11:00-05:00,CBAY,neutral
216240.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,CBAY,neutral
216241.0,13F From Omega Shows Liquidated ~377K Share Stake In Cymabay Therapeutics,2018-11-14 10:31:00-05:00,CBAY,positive
216242.0,55 Biggest Movers From Yesterday,2018-11-14 04:06:00-05:00,CBAY,neutral
216243.0,36 Stocks Moving In Tuesday's Mid-Day Session,2018-11-13 12:54:00-05:00,CBAY,neutral
216244.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-11 09:10:00-05:00,CBAY,neutral
216245.0,CymaBay Therapeutics Inc. Q3 EPS $(0.34) Down From $(0.21) YoY,2018-11-06 16:11:00-05:00,CBAY,neutral
216246.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,CBAY,positive
216247.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,CBAY,neutral
216248.0,CymaBay Announces Initiation Of Seladelpar Global Phase 3 Registration Study (ENHANCE) For Treatment Of Primary Biliary Cholangitis And Additional Corporate Updates,2018-10-30 08:04:00-04:00,CBAY,neutral
216249.0,CymaBay Therapeutics Highlights 2 Abstracts Showing Added Results From Ongoing Phase 2 Study Of Seladelpar In Patients With PBC,2018-10-03 09:04:00-04:00,CBAY,neutral
216250.0,CymaBay Therapeutics Inc. - Common Stock Q2 EPS $(0.30) Misses $(0.25) Estimate,2018-08-09 16:18:00-04:00,CBAY,negative
216251.0,"The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings",2018-08-09 08:39:00-04:00,CBAY,positive
216252.0,"Raymond James Initiates Coverage On CymaBay Therapeutics with Outperform Rating, Announces $20 Price Target",2018-06-28 08:33:00-04:00,CBAY,neutral
216253.0,58 Biggest Movers From Yesterday,2018-06-01 04:47:00-04:00,CBAY,neutral
216254.0,44 Stocks Moving In Thursday's Mid-Day Session,2018-05-31 12:42:00-04:00,CBAY,neutral
216255.0,28 Stocks Moving In Thursday's Pre-Market Session,2018-05-31 08:22:00-04:00,CBAY,neutral
216256.0,13F From Cooperman's Omega Shows New 280K Share Stake In Cymabay Therapeutics,2018-05-15 10:14:00-04:00,CBAY,positive
216257.0,CymaBay Therapeutics Shares down 10.6% After Hours Following Larger-Than-Expected Q1 Loss,2018-05-08 17:53:00-04:00,CBAY,neutral
216258.0,CymaBay Therapeutics Inc. - Common Stock Q1 EPS $(0.32) Misses $(0.14) Estimate,2018-05-08 17:25:00-04:00,CBAY,negative
216259.0,CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis,2018-05-08 08:05:00-04:00,CBAY,neutral
216260.0,38 Biggest Movers From Yesterday,2018-04-12 04:42:00-04:00,CBAY,neutral
216261.0,"Benzinga Pro's Most-Searched Tickers For Wed., Apr. 11, 2018",2018-04-11 15:14:00-04:00,CBAY,neutral
216262.0,28 Stocks Moving In Wednesday's Mid-Day Session,2018-04-11 12:17:00-04:00,CBAY,neutral
216263.0,Mid-Day Market Update: Analogic Falls Following Acquisition News; EyeGate Pharmaceuticals Shares Gain,2018-04-11 12:16:00-04:00,CBAY,positive
216264.0,CymaBay Therapeutics Up 15% After Co. Earlier Reported Positive Results In Phase 2 Seladelpar Study To Be Presented at EASL Conference This Wek,2018-04-11 10:58:00-04:00,CBAY,positive
216265.0,Mid-Morning Market Update: Markets Open Lower; Fastenal Posts In-Line Earnings,2018-04-11 10:15:00-04:00,CBAY,negative
216266.0,CymaBay Announces 'Positive' New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress 2018,2018-04-11 07:47:00-04:00,CBAY,neutral
216267.0,41 Biggest Movers From Yesterday,2018-04-03 04:18:00-04:00,CBAY,neutral
216268.0,Cymabay Therapeutics Shares Up 11.4% After Co. Wednesday Reported Better-Than-Expected Q4 Loss And Strong Sales Beat,2018-03-16 12:34:00-04:00,CBAY,positive
216269.0,"Cymabay Therapeutics Reports Q4 EPS $(0.11) vs $(0.19) Est., Sales $5.2M vs $1.25M Est.",2018-03-15 16:24:00-04:00,CBAY,neutral
216270.0,Evercore ISI Group Initiates Coverage On CymaBay Therapeutics with Outperform Rating,2018-02-13 09:24:00-05:00,CBAY,neutral
216271.0,22 Stocks Moving In Tuesday's Pre-Market Session,2018-02-13 08:00:00-05:00,CBAY,neutral
216272.0,CymaBay Prices Offering Of 11.6M Shares At $10.80/Share,2018-01-30 08:02:00-05:00,CBAY,positive
216273.0,"CymaBay Files For Shelf Offering, No Size Disclosed",2018-01-29 16:42:00-05:00,CBAY,negative
216274.0,"JP Morgan Healthcare Conference Concludes Today, Presenters Include: CymaBay, Orthofix, Analogic, Achaogen, Immunomedics, and Dynavax",2018-01-11 09:07:00-05:00,CBAY,positive
216275.0,CymaBay Earlier Announced Enrollment Has Begun In Long-Term Extension Study Of Seladelpar,2018-01-08 11:58:00-05:00,CBAY,neutral
216276.0,CymaBay Therapeutics Reports Received $5M Milestone Payment For Arhalofenate From Kowa Pharma America,2018-01-08 08:52:00-05:00,CBAY,neutral
216277.0,The Companies That Led 2017's Biotech Rally,2017-12-22 09:50:00-05:00,CBAY,neutral
216278.0,Oppenheimer's Top Stock Picks For December,2017-11-30 10:17:00-05:00,CBAY,positive
216279.0,Cymabay Therapeutics Reports Q3 EPS $(0.21) vs $(0.19) Est.,2017-11-08 16:32:00-05:00,CBAY,neutral
216280.0,"CymaBay Therapeutics Names Sujal Shah Pres, CEO",2017-10-31 08:09:00-04:00,CBAY,neutral
216281.0,29 Top Stock Ideas For October And Beyond,2017-10-16 15:29:00-04:00,CBAY,positive
216282.0,CymaBay Reports Presentation Of Interim Results From Ongoing Phase 2 Study Of Patients With Primary Biliary Cholangitis: Showed 'potential for superior efficacy and better tolerability over existing second-line therapy',2017-10-09 08:02:00-04:00,CBAY,positive
216283.0,15 Biggest Mid-Day Gainers For Wednesday,2017-09-20 12:26:00-04:00,CBAY,neutral
216284.0,"Benzinga's Top Upgrades, Downgrades For September 20, 2017",2017-09-20 09:12:00-04:00,CBAY,positive
216285.0,"Cantor Fitzgerald Initiates Coverage On CymaBay Therapeutics with Overweight Rating, Announces $16.00 Price Target",2017-09-20 06:09:00-04:00,CBAY,negative
216286.0,CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for Treatment of Primary Biliary Cholangitis,2017-09-11 08:00:00-04:00,CBAY,positive
216287.0,"Benzinga's Top Upgrades, Downgrades For August 23, 2017",2017-08-23 09:17:00-04:00,CBAY,positive
216288.0,"Leerink Swann Initiates Coverage On CymaBay Therapeutics with Outperform Rating, Announces $12.00 Price Target",2017-08-23 07:38:00-04:00,CBAY,neutral
216289.0,"CymaBay Therapeutics Reports Publication Of Seladelpar Proof-Of-Concept Study For Primary Biliary Cholangitis In Lancet Gastroenterology, Hepatology",2017-08-15 08:35:00-04:00,CBAY,neutral
216290.0,CymaBay Reports Q2 EPS $(0.31) vs $(0.26) Est.,2017-08-10 16:18:00-04:00,CBAY,neutral
216291.0,5 Biggest Price Target Changes For Thursday,2017-07-20 09:47:00-04:00,CBAY,neutral
216292.0,CymaBay Therapeutics Prices 13M Share Common Stock Offering At $6.50/Share,2017-07-19 08:31:00-04:00,CBAY,positive
216293.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-07-18 08:08:00-04:00,CBAY,neutral
216294.0,CymaBay Reports 10M Share Common Stock Offering,2017-07-17 16:15:00-04:00,CBAY,positive
216295.0,18 Biggest Mid-Day Gainers For Monday,2017-07-17 12:30:00-04:00,CBAY,neutral
216296.0,Mid-Day Market Update: Sevcon Surges Following Acquisition News; TherapeuticsMD Shares Slide,2017-07-17 12:02:00-04:00,CBAY,positive
216297.0,Mid-Morning Market Update: Markets Edge Higher; BlackRock Profit Misses Views,2017-07-17 10:11:00-04:00,CBAY,positive
216298.0,CymaBay Announces 'Positive' Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis,2017-07-17 07:31:00-04:00,CBAY,neutral
216299.0,"Oppenheimer Initiates Coverage On CymaBay Therapeutics with Outperform Rating, Announces $8.00 Price Target",2017-06-23 07:30:00-04:00,CBAY,neutral
216300.0,"CymaBay Reports Q1 EPS $(0.20) vs $(0.27) Est., Sales $4.793M",2017-05-11 16:21:00-04:00,CBAY,neutral
216301.0,"H.C. Wainwright Holding NASH Investor Conference Today; Attendees Include Allergan, Enanta Pharma, Madrigal Pharma, Vascular Biogenics, Albireo Pharma, CymaBay, Gemphire Therapeutics, And Galectin Therapeutics",2017-04-03 08:28:00-04:00,CBAY,neutral
216302.0,"CymaBay Reports Pres, CEO, Harold Van Wart, to Retire; Board Has Promoted Sujal Shah as Interim Pres, CEO",2017-03-29 08:02:00-04:00,CBAY,positive
216303.0,15 Biggest Mid-Day Gainers For Friday,2017-03-24 13:08:00-04:00,CBAY,neutral
216304.0,16 Stocks Moving In Friday's Pre-Market Session,2017-03-24 08:35:00-04:00,CBAY,neutral
216305.0,Cymabay Therapeutics Reports Q4 EPS $(0.30) vs $(0.28) Est.,2017-03-23 16:15:00-04:00,CBAY,neutral
216306.0,18 Biggest Mid-Day Losers For Thursday,2017-02-02 12:50:00-05:00,CBAY,negative
216307.0,CymaBay Prices 5.18M Share Offering At $1.93/Share,2017-02-02 09:15:00-05:00,CBAY,positive
216308.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-02-02 08:19:00-05:00,CBAY,neutral
216309.0,"CymaBay Reports Proposed Public Offering of Common Stock, Terms Not Disclosed",2017-02-01 16:04:00-05:00,CBAY,neutral
216310.0,15 Biggest Mid-Day Gainers For Monday,2017-01-30 12:23:00-05:00,CBAY,neutral
216311.0,Mid-Day Market Update: Dow Falls Over 150 Points; Calithera Biosciences Shares Spike Higher,2017-01-30 12:06:00-05:00,CBAY,positive
216312.0,7 Biggest Price Target Changes For Monday,2017-01-30 10:21:00-05:00,CBAY,neutral
216313.0,"H.C. Wainwright Upgrades CymaBay Therapeutics To Buy, Raises Price Target To $6",2017-01-30 07:25:00-05:00,CBAY,neutral
216314.0,"CymaBay Therapeutics Reports Co. Reached Agreement With EMA On All Key Elements of Planned 3 Program, Similar To Agreed Upon Deal Of FDA",2017-01-05 08:11:00-05:00,CBAY,positive
216315.0,Mid-Afternoon Market Update: NASDAQ Gains Over 50 Points; Evoke Pharma Shares Spike Higher,2017-01-04 14:41:00-05:00,CBAY,positive
216316.0,18 Biggest Mid-Day Gainers For Wednesday,2017-01-04 12:39:00-05:00,CBAY,neutral
216317.0,Mid-Day Market Update: Crude Oil Up Over 1%; Agile Therapeutics Shares Slide,2017-01-04 12:13:00-05:00,CBAY,negative
216318.0,Mid-Morning Market Update: Markets Open Higher; UniFirst Posts Lower Q1 Profit,2017-01-04 10:08:00-05:00,CBAY,positive
216319.0,15 Stocks Moving In Wednesday's Pre-Market Session,2017-01-04 08:20:00-05:00,CBAY,neutral
216320.0,"CymaBay Shares Resume Trade, Now Up 56%",2017-01-03 16:30:00-05:00,CBAY,positive
216321.0,CymaBay Therapeutics Shares to Resume Trade at 4:30 p.m. EST,2017-01-03 16:21:00-05:00,CBAY,positive
216322.0,UPDATE: Kowa Pharma Announces Licensing Deal with CymaBay for Exclusive US Rights to Arhalofenate,2017-01-03 16:02:00-05:00,CBAY,positive
216323.0,CymaBay Therapeutics Reports Deal with Kowa Pharma America to License Gout Compound,2017-01-03 16:01:00-05:00,CBAY,neutral
216324.0,CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis,2016-12-07 08:11:00-05:00,CBAY,neutral
216325.0,CymaBay Reports US Orphan Drug Designation for MBX-8025 for Treatment of Primary Biliary Cholangitis,2016-11-10 08:05:00-05:00,CBAY,neutral
216326.0,CymaBay Reports Q3 EPS $(0.25) vs $(0.29) Est.,2016-11-09 16:56:00-05:00,CBAY,neutral
216327.0,CymaBay Therapeutics Announces a Newly Issued U.S. Patent for the Use of MBX-8025 as a Treatment for Primary Biliary Cholangitis,2016-11-09 08:01:00-05:00,CBAY,neutral
216328.0,CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting,2016-10-20 14:42:00-04:00,CBAY,neutral
216329.0,CymaBay Release Confirms MBX-8025 Received EMA PRIority MEdicines (PRIME) Designation for Treatment of Primary Biliary Cholangitis,2016-10-20 08:10:00-04:00,CBAY,neutral
216330.0,"European Medicines Agency Issues Release Highlighting Recommendations on Eligibility to PRIME Scheme, Includes Cymabay's MBX-8025 Listed as 'Eligibility Granted'",2016-10-19 15:38:00-04:00,CBAY,positive
216331.0,"CymaBay Reports Newly-Issued US Patent for MBX-8025 for Treatment of NAFLD, NASH",2016-10-11 08:09:00-04:00,CBAY,neutral
216332.0,CymaBay Therapeutics Reports Plans to Initiate Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis,2016-10-05 08:05:00-04:00,CBAY,neutral
216333.0,CymaBay Reports Q2 Loss/Share ($0.30) vs Est Loss/Share ($0.32),2016-08-09 16:04:00-04:00,CBAY,neutral
216334.0,Mid-Afternoon Market Update: Daktronics Drops Following Downbeat Results; Galena Biopharma Shares Spike Higher,2016-06-01 14:31:00-04:00,CBAY,positive
216335.0,"H.C. Wainwright Downgrades CymaBay Therapeutics to Neutral, Lowers PT to $2.25",2016-06-01 07:07:00-04:00,CBAY,negative
216336.0,Today's Top 10 Pre-Market Gainers,2016-05-31 09:28:00-04:00,CBAY,positive
216337.0,"CymaBay Reports It Has Discontinued Current Phase 2 Study Of MBX-8025, After Determining Study Met Objective Establishing Proof Of Concept With Marked Improvement In Biochemical Markers Of Cholestasis",2016-05-31 07:03:00-04:00,CBAY,positive
216338.0,Cymabay Therapeutics Reports Q1 EPS $(0.29) Vs Est $(0.28),2016-05-11 16:09:00-04:00,CBAY,neutral
216339.0,"CFO Shah Buys 55,000 Shares of Cymabay Therapeutics @$1.39/Share -Form 4",2016-04-06 16:23:00-04:00,CBAY,positive
216340.0,"H.C. Wainwright Maintains Buy on CymaBay Therapeutics, Lowers PT to $6.00",2016-03-30 07:07:00-04:00,CBAY,negative
216341.0,CymaBay Reports Q4 Loss of $6M vs $12.7M Loss in Same Qtr. Last Year,2016-03-29 16:10:00-04:00,CBAY,negative
216342.0,"Earnings Scheduled For March 29, 2016",2016-03-29 04:15:00-04:00,CBAY,neutral
216343.0,CymaBay Announces Paul Truex &  Robert Weiland To Board of Directors,2016-03-28 16:02:00-04:00,CBAY,neutral
216344.0,CymaBay Therapeutics Reports Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology,2016-03-28 08:02:00-04:00,CBAY,positive
216345.0,Mid-Morning Market Update: Markets Open Higher; Tiffany Q4 Profit Beats Views,2016-03-18 10:03:00-04:00,CBAY,positive
216346.0,CymaBay Therapeutics to Resume Trading at 4:30 PM ET,2016-03-17 16:12:00-04:00,CBAY,neutral
216347.0,UPDATE: CymaBay Offers Results from Pilot Phase 2 Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia,2016-03-17 16:05:00-04:00,CBAY,neutral
216348.0,CymaBay Offers Results from Pilot Phase 2 Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia: Showed Meaningful Reduction in LDL-C for Subset of Patients,2016-03-17 16:04:00-04:00,CBAY,positive
216349.0,CymaBay Therapeutics Shares Halted News Pending,2016-03-17 16:01:00-04:00,CBAY,positive
216350.0,CymaBay Reports Successful Closing of End of Phase 2 Discussions with FDA Related to Arhalofenate,2016-01-20 08:03:00-05:00,CBAY,positive
216351.0,15 Biotechs Making Announcements At The 2015 Piper Jaffray Healthcare Conference,2015-12-01 16:45:00-05:00,CBAY,neutral
216352.0,Cymabay Therapeutics Reports Q3 EPS $(0.27) vs $(0.33) Est.,2015-11-12 16:28:00-05:00,CBAY,neutral
216353.0,CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis,2015-11-10 08:31:00-05:00,CBAY,neutral
216354.0,"CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology (ACR) Annual Meeting, November 6 - 11",2015-11-05 08:42:00-05:00,CBAY,neutral
216355.0,Stocks Hitting 52-Week Lows,2015-11-02 10:18:00-05:00,CBAY,negative
216356.0,Time To Buy Micro-Cap CymaBay Therapeutics: H.C. Wainwright,2015-09-08 15:16:00-04:00,CBAY,neutral
216357.0,Benzinga's Top Initiations,2015-09-08 09:29:00-04:00,CBAY,positive
216358.0,"H.C. Wainwright Initiates Coverage on CymaBay Therapeutics at Buy, Announces $12.00 PT",2015-09-08 07:09:00-04:00,CBAY,neutral
216359.0,"Piper Jaffray Starts CymaBay At Overweight With $4 Target, Discusses MBX-8025",2015-07-21 10:37:00-04:00,CBAY,negative
216360.0,"Piper Jaffray Initiates Coverage on CymaBay Therapeutics at Overweight, Announces $4.00 PT",2015-07-21 07:55:00-04:00,CBAY,negative
216361.0,Morning Market Gainers,2015-07-15 09:49:00-04:00,CBAY,neutral
216362.0,CymbaBay Prices 7.12M Shares at $2.81/Share,2015-07-15 09:11:00-04:00,CBAY,positive
216363.0,Cymabay Reports Proposed Offering Of Stock,2015-07-14 16:03:00-04:00,CBAY,neutral
216364.0,CymaBay Reports Orphan Drug Designation for MBX-8025 for Sever Hypertriglyceridemia,2015-04-22 08:07:00-04:00,CBAY,neutral
216365.0,CymaBay Therapeutics Granted U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia,2015-03-25 08:05:00-04:00,CBAY,positive
216366.0,CymaBay Reports Q4 EPS $(0.87) vs. Est. $(0.47),2015-03-18 16:02:00-04:00,CBAY,neutral
216367.0,CymaBay Announces Preclinical Data Demonstrating Potential of MBX-8025 to Treat Homozygous Familial Hypercholesterolemia,2015-01-28 08:14:00-05:00,CBAY,positive
216368.0,Adage Capital Partners Reports 6.80% Passive Stake in Cymabay Therapeutics as of January 14,2015-01-23 11:40:00-05:00,CBAY,positive
216369.0,Stifel Raises Price Target On CymaBay Therapeutics,2015-01-20 10:22:00-05:00,CBAY,neutral
216370.0,5 Healthcare Stocks With The Highest EPS,2015-01-20 09:24:00-05:00,CBAY,neutral
216371.0,Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate,2015-01-12 08:05:00-05:00,CBAY,positive
216372.0,Morning Market Losers ,2014-09-30 09:51:00-04:00,CBAY,negative
216373.0,CymaBay Therapeutics Completes Enrollment In Arhalofenate Phase 2b Study ,2014-09-29 08:19:00-04:00,CBAY,neutral
216374.0,"Roth Capital Initiates Coverage on CymaBay at Buy, Announces $14.00 PT",2014-09-19 05:36:00-04:00,CBAY,neutral
216375.0,"Cymabay Therapeutics CFO Shah Buys 10,000 Shares @$7.44/Share -Form 4",2014-09-17 18:37:00-04:00,CBAY,positive
216376.0,"Stifel Nicolaus Initiates Coverage on CymaBay at Buy, Announces $10.00 PT",2014-09-17 06:05:00-04:00,CBAY,neutral
216377.0,Morning Market Losers ,2014-07-22 10:00:00-04:00,CBAY,negative
216378.0,CymaBay Therapeutics Commences 3.5M Share Offering,2014-07-17 06:53:00-04:00,CBAY,positive
216379.0,CymaBay Therapeutics Spokesperson Says No News to Account for Extreme Volatility in Share Price Today,2014-07-09 10:37:00-04:00,CBAY,neutral
216380.0,CymaBay Therapeutics Shares Resume Trading Following Second Circuit-Breaker Halt; Now Up 53%,2014-07-09 10:17:00-04:00,CBAY,positive
